Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging
| Autor: | Daniel Skovronsky, Ming Lu, Keith A. Johnson, Alan Carpenter, Reisa A. Sperling, Carl H. Sadowsky, Mark A. Mintun, Christopher Gidicsin, Adam S. Fleisher, Michel J. Pontecorvo, Christopher M. Clark, Eric M. Reiman, Jeremy Carmasin, Michel Grundman, P. Murali Doraiswamy, Marwan N. Sabbagh, R E Coleman, Jacqueline E. Maye, Abhinay D. Joshi |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Apolipoprotein E Aging Fluorine Radioisotopes Pathology medicine.medical_specialty Amyloid Epidemiology Apolipoprotein E4 Phases of clinical research Amyloidogenic Proteins Disease behavioral disciplines and activities Article Cellular and Molecular Neuroscience Developmental Neuroscience Alzheimer Disease Internal medicine Stilbenes mental disorders medicine Humans Dementia Cognitive Dysfunction Cognitive impairment Aged Aged 80 and over Aniline Compounds medicine.diagnostic_test Health Policy Middle Aged medicine.disease Psychiatry and Mental health Positron emission tomography Positron-Emission Tomography Female Neurology (clinical) Geriatrics and Gerontology Alzheimer's disease Mental Status Schedule Psychology |
| Zdroj: | Alzheimer's & Dementia. 9 |
| ISSN: | 1552-5279 1552-5260 |
| Popis: | Objective To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs). Methods Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative. Results Florbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty-four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E e4 carrier status. Conclusions: The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|